✦ LIBER ✦

Is there a need for more precise definitions of bioavailability?

✍ Scribed by L. P. Balant

Publisher: Springer
Year: 1991
Tongue: English
Weight: 435 KB
Volume: 40
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00280064

No coin nor oath required. For personal study only.

✦ Synopsis

After evaluation of the present definitions in a set of particular cases, it was agreed that there was no need for "more precise" definitions and that the current ones were adequate in the majority of cases. However, it was felt that the present definitions might be improved, in particular in view of the existence of non-systemically acting drugs and future "targeted drugs". Thus, the FDA definition might be modified as follows: "Bioavailability means the rate and extent to which the active drug ingredient or therapeutic moiety from a drug product becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action".

📜 SIMILAR VOLUMES

Is there a need for immunopharmacologic

Is there a need for immunopharmacologic guidance of anti–tumor necrosis factor therapies?

✍ Klaus Bendtzen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 1 views

Histopathological grading of cervical in

Histopathological grading of cervical intraepithelial neoplasia (CIN)—is there a need for change?

✍ A. J. Robertson 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 284 KB

Endpoints in cancer clinical trials: is

Endpoints in cancer clinical trials: is there a need for measuring quality of life?

✍ Ronald Feld 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 456 KB

Prevalence and predictors of ocular mani

Prevalence and predictors of ocular manifestations of RA: is there a need for routine screening?

✍ Holly Piper; Karen MJ Douglas; Gareth J Treharne; Debbie L Mitton; Sajjad Haider 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Identification of a family with nonspeci

Identification of a family with nonspecific mental retardation (MRX79) with the A140V mutation in the MECP2 gene: Is there a need for routine screening?

✍ Birgitta Winnepenninckx; Vanessa Errijgers; France Hayez-Delatte; Edwin Reyniers 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

Mutations in the methyl-CpG-binding protein 2 (MECP2) cause Rett syndrome, a severe neurodevelopmental disorder occurring predominantly in females. Male patients with Rett syndrome are extremely rare, as the Rett-causing mutations in the MECP2 gene are usually lethal in hemizygous males. However, di

Single-center series and systematic revi

Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor α therapy: Is there a need for more comprehensive screening procedures?

✍ Nannini, Carlotta ;Cantini, Fabrizio ;Niccoli, Laura ;CassarÀ, Emanuele ;Salvara 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views